Skip to main content
. 2022 Nov 12;66:101635. doi: 10.1016/j.molmet.2022.101635

Figure 6.

Figure 6

(A) Kinetic evolution of simulated drug uptake and binding (dark blue), and cellular response (green), (B) Raman spectrum of the drug, doxorubicin (dark blue), simulated spectral signature of drug binding (cyan) and of the subsequent cellular response (green), (C) predicted kinetic evolution of the MCR-ALS components, (D) MCR-ALS components, extracted after 50 iterations, (E) evolution of the kinetic constraint constants over 200 iterations of the MCR-ALS algorithm, (F) initial and final (after 200 iterations) constants employed in the MCR-ALS model. (Reproduced with permission from [30]).